Creatine Study

Creatine+ Study 1

We are seeking 30 participants, age 21+, to take part in a 15-day study evaluating the safety and tolerability of Qualia Creatine+.

The purpose of this study is to gather information on participants’ experiences using Qualia Creatine+, focusing on safety, tolerability, and general feedback. This is an open-label study, meaning all participants will receive the active product.

Each participant will receive a free 30-day supply of Qualia Creatine+ and take one scoop daily, mixed with water or a beverage of choice, with or without food. Participants will complete brief surveys before starting the product and at key points over the first 15 days. A final follow-up survey will be sent around day 30 to collect additional feedback and reviews that may be featured in our marketing materials.

Pre-screening surveys are used solely to determine eligibility for participation. Data will be securely stored on Qualia Life Sciences servers, accessible only to authorized personnel.

Spots are limited—apply now to be among the first to experience Qualia Creatine+.

*US only

*This study is being conducted by Qualia Life Science

REQUIREMENTS AND CRITERIA:

Inclusion Criteria:

• Provide voluntary, written, informed consent to participate in the study
• Agree to provide a valid cell phone number and are willing to receive communications through text
• Can read and write English
• Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
• Willing to complete questionnaires, records, and diaries associated with the study.
• Healthy male and female participants aged 21+ years

Exclusion Criteria:

• Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
• Known food intolerances/allergy to any ingredients in the product
• Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
• Having had a significant cardiovascular event in the past 6 months
• Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
• On immunosuppressive therapy
• Individuals who were deemed incompatible with the test protocol
• Adults lacking capacity to consent